Ammonia
[Ammonia ]
EPTIS Ringversuch Nr. 142631 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142631 https://www.eptis.bam.de/pts142631
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | The Ammonia programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. Ammonia is analysed as part of the diagnostic investigation of the unconscious patient, to support the diagnosis of Reye’s syndrome and hepatic encephalopathy and in identification and management of a urea cycle defect. A range of Ammonia samples are distributed covering both normal and pathological levels including those seen in urea cycle defects. The material is liquid human serum, this matrix is commutable and compatible with all enzymatic methods assayed on laboratory analysers, dry slide chemistry analysers and Point of Care devices (POCT). Three aqueous samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of a panel of 6 linearly related samples distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Ammonia levels covering relevant clinical and analytical range. - Samples suitable for Laboratory and POCT devices. - Commutable Liquid human serum. - Programme assesses laboratory and method performance, including bias, within and between batch imprecision and linearity. - Analytical Performance Specification based on Milan Model 3. For more information: https://www.weqas.com/services/eqa/ammonia/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | Samples suitable for Laboratory and POCT devices. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 0.5mL.) | ||||||
| Der Ringversuch wird durchgeführt seit | 2002 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.